04- PHARMA/BIOTECH

Lilly Spends >$150m And Share Price Down 14%

Solanezumab ‘fails’ in Alzheimer’s at last Hate to say ‘we told you so’ all along! Julian, Bengt and I said so in our review article last year. There’s no substitute for the good old fashioned ordered process of clinical development – Learn first (Phase II) then Confirm (Phase III) Biogen (aducanumab) next? >>>> http://www.fiercebiotech.com/biotech/alzheimer-s-hopes-dashed-as-lilly-gives-up-amyloid-drug-solanezumab?utm_medium=nl&utm_source=internal&mrkid=938224&mkt_tok=eyJpIjoiWVdNMVltTXlPR1kyWlRjdyIsInQiOiI1NGFBR2dHK1BNXC9GRmkxdVVcL3I5K2I3dEtiVWkwbXppbTdPdmhpQkJlRFwvK1dvK0lmYmt4a25WZVRhbWJQd1NQQ3ZibkZJWlwvUzJzZ1Njck9hXC9qVGd3M0ptZFZmVVduZVBNRnFyVHhIR0xJPSJ9

Read More

A Hot Topic: Reducing Screen Failures In AD

My mate Tom’s approach to reducing screen failures in AD A complex statistical adaptive technique – REALLY! >> http://www.clinicalleader.com/doc/improving-screen-failure-and-recruitment-rates-in-alzheimer-s-disease-clinical-trials-0001?vm_tId=1965472&user=c4f6390a-527b-4ba6-97c0-6eff283b345d&utm_source=et_6212879&utm_medium=email&utm_campaign=CLNCL_11-21-2016&utm_term=c4f6390a-527b-4ba6-97c0-6eff283b345d&utm_content=Improving+Screen+Failure+And+Recruitment+Rates+In+Alzheimer%27s+Disease+Clinical+Trials  

Read More

Plethora Markets Fortacin For PE

We worked on the Phase II premature ejaculation programme in 2007 What have they been doing for nearly 10 years! >>> http://www.pharmatimes.com/news/uk_launch_for_premature_ejaculation_spray_1176726?utm_source=PT+Daily+Newsletter&utm_medium=email&utm_campaign=pt+daily+news+alert

Read More

Binge Eating Disorder (Shire)

Trust my old company to come up with this one 🙂 >>>> https://www.shire.com/en/newsroom/2016/october/yjizb2 I didn’t even know BED was an illness!

Read More